Q32 Bio will report topline 36-week results from Part B of its Phase 2a SIGNAL-AA clinical trial for bempikibart, a drug targeting severe alopecia areata, on July 13, 2026. The company will hold a conference call and webcast to discuss the data, which is important as bempikibart aims to offer a new treatment option for this autoimmune disease with limited therapies. Investors and interested parties can access the live event via Q32 Bio's website or phone. This update is a key milestone in Q32 Bio's development of innovative therapies for autoimmune conditions.
Toast's Chief Revenue Officer has sold nearly 14,000 shares as the company's stock price has surged over 50% in the past three months. This insider sale comes at a time when investor confidence appears strong, reflecting positive market sentiment tow...
Kohl's reported a strong adjusted EPS of $1.28 for Q2, more than doubling analyst expectations due to a 43% gross margin boosted by one-time tariff refunds. However, the retailer's total revenue and comparable sales fell by 0.9%, marking the 18th con...
Royal Bank of Canada reported strong Q3 2026 results, surpassing earnings per share estimates with $3.07 versus $2.89 expected, marking a 6.23% positive surprise and continuing a streak of four quarters beating expectations. Revenue also exceeded for...
Evercore ISI increased its price target for Williams-Sonoma to $245 following a strong Q2 performance, with revenue up 6.7% to $1.96 billion and comparable sales rising 6.2%, beating expectations. The gross margin improved to 51.6%, partly due to one...
RBC Capital reaffirmed its 'Sector Perform' (hold) rating on FactSet, increasing the price target from $240 to $304 as of August 27, 2026. Despite this optimistic price target adjustment, the broader market remains cautious, with an average 'Reduce' ...
